Template:Hydralazine: Difference between revisions
Jump to navigation
Jump to search
Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8..." |
No edit summary |
||
Line 29: | Line 29: | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Hydralazine tablet nonclinical toxicology|Nonclinical Toxicology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Hydralazine tablet nonclinical toxicology|Nonclinical Toxicology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Hydralazine tablet how supplied storage and handling|How Supplied/Storage and Handling]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Hydralazine tablet labels and packages|Labels and Packages]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Hydralazine tablet labels and packages|Labels and Packages]] |
Latest revision as of 15:55, 11 March 2014
Hydralazine |
---|
HYDRALAZINE tablet® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings |
Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Labels and Packages |
HYDRALAZINE injection® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings |
Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Labels and Packages |
Clinical Trials on Hydralazine |
ClinicalTrials.gov |